{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-25-000099","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.793143+00:00","generated_at":"2026-05-22T21:45:13.077499+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neurocrine Q1: INGREZZA $545M (+8%), CRENESSITY $14.5M; GAAP EPS $0.08; reaffirms FY25 guide","bullets":["INGREZZA net product sales $545M in Q1 2025, up 8% YoY; CRENESSITY sales $14.5M with 413 patient enrollment forms.","GAAP net income $7.9M ($0.08 EPS) vs $43.4M ($0.42) YoY; Non-GAAP net income $71.5M ($0.70) vs $124.8M ($1.20).","Reaffirmed 2025 INGREZZA net sales guidance of $2.5-$2.6B; total R&D guidance $960M-$1.01B GAAP.","Initiated Phase 3 registrational programs for osavampator in MDD and NBI-568 in schizophrenia.","Appointed Sanjay Keswani, M.D., as Chief Medical Officer effective June 2, 2025; authorized $500M share repurchase, $150M completed."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-25-000099","json":"https://secwatch.observer/filing/0000914475-25-000099.json","markdown":"https://secwatch.observer/filing/0000914475-25-000099.md","text":"https://secwatch.observer/filing/0000914475-25-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000099/0000914475-25-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000099/nbix-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T21:45:13.077499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}